These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
238 related articles for article (PubMed ID: 25081375)
1. GOLPH3 high expression predicts poor prognosis in patients with resected non-small cell lung cancer: an immunohistochemical analysis. Zhang Y; Ma M; Han B Tumour Biol; 2014 Nov; 35(11):10833-9. PubMed ID: 25081375 [TBL] [Abstract][Full Text] [Related]
2. TGF-β1 protein expression in non-small cell lung cancers is correlated with prognosis. Huang AL; Liu SG; Qi WJ; Zhao YF; Li YM; Lei B; Sheng WJ; Shen H Asian Pac J Cancer Prev; 2014; 15(19):8143-7. PubMed ID: 25338997 [TBL] [Abstract][Full Text] [Related]
3. Retinoic acid-related orphan receptor C isoform 2 expression and its prognostic significance for non-small cell lung cancer. Huang Q; Fan J; Qian X; Lv Z; Zhang X; Han J; Wu F; Chen C; Du J; Guo M; Hu G; Jin Y J Cancer Res Clin Oncol; 2016 Jan; 142(1):263-72. PubMed ID: 26319393 [TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of TAZ expression in resected non-small cell lung cancer. Xie M; Zhang L; He CS; Hou JH; Lin SX; Hu ZH; Xu F; Zhao HY J Thorac Oncol; 2012 May; 7(5):799-807. PubMed ID: 22481233 [TBL] [Abstract][Full Text] [Related]
5. Vasohibin-1 expression detected by immunohistochemistry correlates with prognosis in non-small cell lung cancer. Zhang T; Yu TT; Zhang DM; Hou XM; Liu XJ; Zhao D; Shan L Med Oncol; 2014 May; 31(5):963. PubMed ID: 24748406 [TBL] [Abstract][Full Text] [Related]
6. Overexpression of muscarinic receptor 3 promotes metastasis and predicts poor prognosis in non-small-cell lung cancer. Lin G; Sun L; Wang R; Guo Y; Xie C J Thorac Oncol; 2014 Feb; 9(2):170-8. PubMed ID: 24419413 [TBL] [Abstract][Full Text] [Related]
7. HSP90B1 overexpression predicts poor prognosis in NSCLC patients. Xu Y; Chen Z; Zhang G; Xi Y; Sun R; Wang X; Wang W; Chai F; Li X Tumour Biol; 2016 Oct; 37(10):14321-14328. PubMed ID: 27599983 [TBL] [Abstract][Full Text] [Related]
8. High TBX2 expression predicts poor prognosis in non-small cell lung cancer. Zhang Z; Guo Y Neoplasma; 2014; 61(4):476-80. PubMed ID: 25027744 [TBL] [Abstract][Full Text] [Related]
9. Beclin 1 and p62 expression in non-small cell lung cancer: relation with malignant behaviors and clinical outcome. Wang X; Du Z; Li L; Shi M; Yu Y Int J Clin Exp Pathol; 2015; 8(9):10644-52. PubMed ID: 26617774 [TBL] [Abstract][Full Text] [Related]
10. Clinical significance of RUNX2 expression in patients with nonsmall cell lung cancer: a 5-year follow-up study. Li H; Zhou RJ; Zhang GQ; Xu JP Tumour Biol; 2013 Jun; 34(3):1807-12. PubMed ID: 23471668 [TBL] [Abstract][Full Text] [Related]
11. An immunohistochemical study of cyclin-dependent kinase 5 (CDK5) expression in non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC): a possible prognostic biomarker. Wei K; Ye Z; Li Z; Dang Y; Chen X; Huang N; Bao C; Gan T; Yang L; Chen G World J Surg Oncol; 2016 Feb; 14(1):34. PubMed ID: 26860827 [TBL] [Abstract][Full Text] [Related]
12. ADAM17 is overexpressed in non-small cell lung cancer and its expression correlates with poor patient survival. Ni SS; Zhang J; Zhao WL; Dong XC; Wang JL Tumour Biol; 2013 Jun; 34(3):1813-8. PubMed ID: 23475633 [TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of annexin II expression in non-small cell lung cancer. Luo CH; Liu QQ; Zhang PF; Li MY; Chen ZC; Liu YF Clin Transl Oncol; 2013 Nov; 15(11):938-46. PubMed ID: 23529818 [TBL] [Abstract][Full Text] [Related]
15. HDGF and ADAM9 are novel molecular staging biomarkers, prognostic biomarkers and predictive biomarkers for adjuvant chemotherapy in surgically resected stage I non-small cell lung cancer. Zhang J; Chen N; Qi J; Zhou B; Qiu X J Cancer Res Clin Oncol; 2014 Aug; 140(8):1441-9. PubMed ID: 24770635 [TBL] [Abstract][Full Text] [Related]
16. RBX1 expression is an unfavorable prognostic factor in patients with non-small cell lung cancer. Xing R; Chen KB; Xuan Y; Feng C; Xue M; Zeng YC Surg Oncol; 2016 Sep; 25(3):147-51. PubMed ID: 27566015 [TBL] [Abstract][Full Text] [Related]
17. PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups. Schmidt LH; Kümmel A; Görlich D; Mohr M; Bröckling S; Mikesch JH; Grünewald I; Marra A; Schultheis AM; Wardelmann E; Müller-Tidow C; Spieker T; Schliemann C; Berdel WE; Wiewrodt R; Hartmann W PLoS One; 2015; 10(8):e0136023. PubMed ID: 26313362 [TBL] [Abstract][Full Text] [Related]
18. Overexpression of MAC30 is associated with poor clinical outcome in human non-small-cell lung cancer. Han KY; Gu X; Wang HR; Liu D; Lv FZ; Li JN Tumour Biol; 2013 Apr; 34(2):821-5. PubMed ID: 23229099 [TBL] [Abstract][Full Text] [Related]
19. Elevated expression of BIRC6 protein in non-small-cell lung cancers is associated with cancer recurrence and chemoresistance. Dong X; Lin D; Low C; Vucic EA; English JC; Yee J; Murray N; Lam WL; Ling V; Lam S; Gout PW; Wang Y J Thorac Oncol; 2013 Feb; 8(2):161-70. PubMed ID: 23287853 [TBL] [Abstract][Full Text] [Related]
20. Clinical significance of IGF1R expression in non-small-cell lung cancer. Nakagawa M; Uramoto H; Oka S; Chikaishi Y; Iwanami T; Shimokawa H; So T; Hanagiri T; Tanaka F Clin Lung Cancer; 2012 Mar; 13(2):136-42. PubMed ID: 22133293 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]